



ISSN: 0975-833X

Available online at <http://www.journalcra.com>

INTERNATIONAL JOURNAL
OF CURRENT RESEARCH

International Journal of Current Research
Vol. 12, Issue, 03, pp.10731-10734, March, 2020

DOI: <https://doi.org/10.24941/ijcr.38197.03.2020>

RESEARCH ARTICLE

GALLBLADDER CLEAR CELL CARCINOMA: A CASE REPORT

*Bayanduuren, B., Altankhuyag, B., Enkhbayar, Batbaatar, G., Mishigdorj, L., Bulganch and Gonchigsuren, D.

Grand med Hospital, Ulaanbaatar, Mongolia

ARTICLE INFO

Article History:

Received 24th December, 2019

Received in revised form

10th January, 2020

Accepted 28th February, 2020

Published online 30th March, 2020

Key Words:

Clear cell Carcinoma,
Gallstone Disease, Open Cholecystectomy,
Intraoperative Cholangiogram, Gallbladder
Cancer.

ABSTRACT

Introduction: Worldwide, the highest incidence rates (up to 7.5 per 100,000 in men and 23 per 100,000 in women) occur among populations in the Western part of South America (Chile and Peru), in North American Indians, in Mexican Americans, and in northern India. The best characterized risk factor for the development of gallbladder cancer is chronic inflammation associated with gallstones. Metastatic clear cell carcinoma in the gallbladder is extremely rare, with reported frequencies of less than 0.6% in large autopsy reviews. **Case presentation:** 54-year-old female, with no prior medical conditions presented with a 10 days history of upper abdominal pain. Last 4 days ago right abdomen upper quadrant pain, vomiting. Routine hematological leukocytosis and biochemical tests were CRP increased. An abdominal ultrasound revealed the gallbladder is enlargement, about 6.0*3.0 cm like the mudstone in the gallbladder. GB wall thickening/double/. Common bile duct is dilated /1.2cm/. Computed tomography imaging: Moderate thickening with surrounding mild edematous changes in wall of the gallbladder. Size of the GB is moderated dilated with diffuse sludges. IHBD is no dilated, CBD is mild dilated 1.2 cm and no sign of biliary tract obstruction. An open cholecystectomy. Upon pathologic investigation, the morphologic and immunophenotypic features supported a diagnosis of clear cell variant of gallbladder carcinoma. **Discussion:** Gallbladder cancer was first described in 1777. Clear cell gallbladder carcinoma was first reported in 192. Clear cell carcinoma represents on average over 90% of all malignancies of the kidney. Approximately 20%-30% of patients with clear cell carcinoma have metastatic disease at presentation and nearly 50% of patients with advanced disease die within 5 years of diagnosis. **Conclusion:** Clear cell carcinoma very rare disease. Our team diagnosed during surgery and histological analysis. As a result of the surgery patient was completely healed and discharged from hospital. After from hospital discharged, we sent to national cancer center.

Copyright © 2020, Bayanduuren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Bayanduuren, B., Altankhuyag, B., Enkhbayar, Batbaatar, G., Mishigdorj, L., Bulganch and Gonchigsuren, D., 2020. "Gallbladder clear cell carcinoma: a case report", *International Journal of Current Research*, 12, (03), 10731-10734.

INTRODUCTION

Incidence of 6500 cases annually in the United States, gallbladder cancer is the fifth most common gastrointestinal tract malignancy in this country. Incidence increases with age and is two to six times higher in women than in men (1.3.6). Worldwide, the highest incidence rates (up to 7.5 per 100,000 in men and 23 per 100,000 in women) occur among populations in the Western part of South America (Chile and Peru), in North American Indians, in Mexican Americans, and in northern India (Duffy et al., 2008; Levy et al., 2001). The best characterized risk factor for the development of gallbladder cancer is chronic inflammation associated with gallstones (7.10).

Although only 0.5–3% of patients with cholelithiasis will develop gallbladder cancer, gallstones are present in 70–90% of patients diagnosed with gallbladder cancer (11.13). However, the 20-year risk of developing cancer for patients with gallstones is less than 0.5 percent for the overall population and 1.5 percent for high-risk groups. Polypoid lesions of the gallbladder are associated with increased risk of cancer, particularly in polyps larger than 10mm (2.4.8). The calcified "porcelain" gallbladder is associated with more than a 20 percent incidence of gallbladder carcinoma (1-5). When diagnosed, about 25 percent of gallbladder cancers are localized to the gallbladder wall, 35 percent have regional nodal involvement and /or extension into adjacent liver, and approximately 40 percent have distant metastasis. Metastatic tumors to the gallbladder are uncommon. The most common metastatic tumors to the gallbladder are metastatic melanomas and metastatic carcinomas from stomach, pancreas, ovary, bile ducts, colon and breast (Agha, 2016).

*Corresponding author: Bayanduuren, B.,
Grand med Hospital, Ulaanbaatar, Mongolia.

Metastatic clear cell carcinoma in the gallbladder is extremely rare, with reported frequencies of less than 0.6% in large autopsy reviews (5.7). Clear cell carcinoma is a rare tumor accounting for 3% of all malignancies in adults and 85% of primary renal tumors. The most frequent sites of metastasis are lung (55%), regional lymph nodes (34%), liver (33%), bones (32%), adrenal (19%), contralateral kidney (11%) and CNS (6%) (2.8.12).

Case report: Patient was a 54-year-old female. Patient was right upper abdominal pain and epigastric middle pain. Nausea and vomiting. Pain was started 10 days ago, after ate dumplings. No history of previous any gastrointestinal disease. The physical examination: Tenderness in right hypochondrium. Lump in the hypochondrium. Murphy's sign was positive. The patient's in blood test increased white blood cell and C- reactive protein. Table 1/. No cancer tumor markers were performed at the time.

Radiology examination

Abdominal ultrasound examination: Gallbladder is enlargement, about 6.0*3.0 cm like the mudstone in the gallbladder. GB wall thickening /double/. Common bile duct is dilated /1.2cm/ //Figure.1

Abdominal contrast CT examination: Moderate thickening with surrounding mild edematous changes in wall of the gallbladder. Size of the GB is moderated dilated with diffuse sludges. IHBD is no dilated, CBD is dilated 1.2 cm and no sign of biliary obstruction. Normal parenchymal contour and thickness of both kidneys. No renal masse (Figure. 2-4).

Treatment: We were emergency surgery of under general anesthesia open cholecystectomy and intraoperative cholangiogram. During surgery gallbladder was distended and gallbladder wall very thickness, hardness (Figure. 5-7). In cholangiogram common bile duct no obstructive sign (Figure. 8-9).

Histology examination: Undifferentiated carcinoma on the background of chronic cholecystitis. Done consultation from Campus medicus Europa.

Campus medicus Europa: This is rare case of a clear cell carcinoma in the gallbladder with a high mitotic activity. A metastatic renal cell carcinoma has to be ruled out (Figure 10).

DISCUSSION

Gallbladder cancer was first described in 1777(4-8). Clear cell gallbladder carcinoma was first reported in 1926(1.2,7). Clear cell carcinoma represents on average over 90% of all malignancies of the kidney (3.5.7). Approximately 20%-30% of patients with clear cell carcinoma have metastatic disease at presentation and nearly 50% of patients with advanced disease die within 5 years of diagnosis (1.12). The risk factors for gallbladder cancer are the presence of a stone larger than 2 cm in diameter inside the gallbladder, polyps larger than 1 cm in diameter inside the gallbladder, choledochal cysts, typhoid and **Opisthorchis**disease, primary sclerosing cholangitis, porcelain gallbladder, and excessive consumption of red meat and tobacco (5.7). High risk factors include of gallbladder cancer associated with 80–90% in cholelithiasis (3.6). Laboratory tests of tumor markers, such as CA19-9 and CEA, usually were positive (1.9-12).

Table 1. Changes of blood test

Name	Reference	Result
<i>CBC</i>		
WBC	4-10*10 ³ /L	11.5*10 ³ /L
Neutrophil	34-71%	76%
<i>Biochemistry</i>		
CRP	0-5mg/l	108.19mg/l
Fibrinogen	2-4g/l	7.12g/l

Blood test, 2019



Figure 1. Abdominal ultrasound




Figure 2. Contrast CT abdomen /frontal/




Figure 3. Contrast CT abdomen /coronal




Figure 4. Contrast CT abdomen: Gallbladder wall thickness



Figure 7. Gallbladder carcinoma




Figure 5. Gallbladder carcinoma with stone




Figure 8. Intraoperative cholangiogram/ by contrast/




Figure 6. Gallbladder carcinoma




Figure 9. Intraoperative cholangiogram/ by contrast




Figure 10. Clear cell carcinoma in the gallbladder with a high mitotic activity

Surgical treatment of gallbladder cancer varies by case. Stage of the disease, tumor localization and whether it was the first identified tumor or recurred tumor are important factors that will decide surgical method (1.4.8). While in some appropriate patients, cholecystectomy is sufficient, some cases may require major operations such as hepatectomy, resection of the bile duct and pancreaticoduodenectomy (5.9.12). In stage I (T1, N0) gallbladder cancer cases have reported a 100% 5-year survival with only cholecystectomy (4.9). Prior to establishing that clear cell carcinoma is a primary gallbladder cancer, it is appropriate to clinically investigate possible secondary focuses, in particular the kidneys in terms of metastasis (1.2). Global incidence of RCC continues to grow steadily with the increase in incidentally discovered lesions during imaging studies (11.12). Up to 50%-60% of RCCs may be incidentally found in asymptomatic patients at abdominal imaging studies performed for other indications (4.5). Recent advances in the understanding of the genetic basis of RCC have provided unique insights into the underlying histologic and biological diversity of renal cancer (3-6). Renal cell carcinoma is considered a byproduct of genetic events that may involve gain-of-function of proto-oncogenes, loss-of-function of cancer suppressor genes, or both (1.7.8). Different histologic subtypes of renal cell carcinoma have characteristic clinical, genetic, and biological profiles (9.12). Clear cell carcinoma is the approximately 70%-75% of all renal cell carcinomas (Wistuba, 1999; Albores-Saavedra, 1996; Albores-Saavedra, 1992; Gakiopoulou, 2007; Misra, 2003). Acute cholecystitis as a clinical presentation is associated with poor prognosis (Misra, 2003). The five-year survival rate following cholecystectomy for RCC is 35-50%. According to Chung et al 63% of patients with one gallbladder metastasis have a two-year survival, while in the case of multiple metastases this rate decreases to 23% following cholecystectomy (Albores-Saavedra, 1992; Gakiopoulou, 2007; Misra, 2003; Bittinger, 1996).

Conclusion

Clear cell carcinoma very rare disease. Our team diagnosed during surgery and histological analysis. As a result of the surgery patient was completely healed and discharged from hospital. After from hospital discharged, we sent to national cancer center.

REFERENCES

- Agha, R.A. et al., 2016. The SCARE statement: consensus-based surgical case report guidelines, *Int. J. Surg. (Lond., Engl.)* 34 180–186 /4
- Albores-Saavedra J., Henson DE., Sobin LH. 1992. The WHO histological classification of tumors of the gallbladder and extrahepatic bile ducts. A commentary on the second edition. *Cancer.*70(2):410–414.
- Albores-Saavedra J., Molberg K., Henson DE. 1996. Unusual malignant epithelial tumors of the gallbladder. *Semin Diagn Pathol.* 13(4):326–338.
- Bittinger A., Altekruiger I., Barth P. 1996. Clear cell carcinoma of the gallbladder: a histological and immunohistochemical study. *Pathol Res Pract.*, 191(12):1259–1265.
- Duffy A., Capanu M., Abou-Alfa GK., et al., 2008. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) *J Surg Oncol.* 98(7):485–489.
- Gakiopoulou H., Givalos N., Liapis G., Agrogiannis G., Patsouris E., Delladetsima I. 2007. Hepatoid adenocarcinoma of the gallbladder. *Dig Dis Sci.*, 52(12):3358–3362.
- Lazcano-Ponce EC., Miquel JF., Muñoz N. et al., 2001. Epidemiology and molecular pathology of gallbladder cancer. *CA: Cancer J Clin.*, 51(6):349–364
- Levy AD., Murakata LA., Rohrmann CA., Jr Gallbladder carcinoma: radiologic-pathologic correlation. *Radiographics.* 2001;21(2):295–314. questionnaire, 549–555.
- Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. *Lancet Oncol.* 2003;4(3):167–176.
- Sheth S., Bedford A., Chopra S. 2000. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. *Am J Gastroenterol.* 2000;95(6):1402–1410.
- Surveillance, Epidemiology and End-Results Program (SEER) The Four Most Common Cancers for Different Ethnic Populations 2013. Bethesda, MD: National Cancer Institute; 2013.
- Wistuba II., Albores-Saavedra J. 1999. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. *J Hepatobiliary Pancreat Surg.* 6:237–244.
- Wistuba II., Gazdar AF. 2004. Gallbladder cancer: lessons from a rare tumour. *Nat Rev Cancer.*, 4(9):695–706.
